We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Dako, Cell Signalling Tech Partner with Companion Diagnostics

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Dako, Cell Signalling Tech Partner with Companion Diagnostics "

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Dako, an Agilent Technologies company, today announced that they have entered into a strategic partnership to supply antibodies for use in Dako-branded companion diagnostics products.

"We are pleased to work with CST in the development of high-quality, cutting-edge companion diagnostic products that will be an important tool in the diagnosis and treatment of cancer," said Jacob Thaysen, president of Agilent's Diagnostics and Genomics Group.

The market for companion diagnostics is steadily growing, as personalized medicine may improve patient care and assist in managing healthcare costs by targeting treatments to individuals more likely to benefit from specific therapies, particularly in the treatment of cancer.

Today's announcement follows several other collaborative agreements in the companion diagnostics area. Agilent's Dako business has a record of successful long-term partnerships with companies such as Pfizer, AstraZeneca, Bristol-Myers Squibb, Merck & Co., Amgen and Eli Lilly, and it continues to attract new partners.

"CST recognizes that companion diagnostic products have great potential to improve the way we diagnose and treat patients with cancer," said Michael J. Comb, CEO of CST. "We believe this partnership will allow our products to contribute to the advancement of personalized medicine."
The financial details of the agreement were not disclosed.